Charles River Laboratories International Inc
CRL193.030USD
-1.340-0.69%
Close 12/12, 16:00（ET）Quotes delayed by 15 min
9.50BMarket Cap
LossP/E TTM
More Details of Charles River Laboratories International Inc Company
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Charles River Laboratories International Inc Info
Ticker SymbolCRL
Company nameCharles River Laboratories International Inc
IPO dateJun 23, 2000
CEOFoster (James C)
Number of employees18600
Security typeOrdinary Share
Fiscal year-endJun 23
Address251 Ballardvale St
CityWILMINGTON
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code01887
Phone17812226000
Websitehttps://www.criver.com/
Ticker SymbolCRL
IPO dateJun 23, 2000
CEOFoster (James C)
Company Executives of Charles River Laboratories International Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James C. Foster
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
267.96K
+6.88%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
57.72K
+24.38%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
17.89K
+48.67%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
12.88K
+69.56%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
12.48K
-8.77%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+23.86%
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
3.96K
+31.35%
Ms. Reshema Kemps-Polanco
Ms. Reshema Kemps-Polanco
Independent Director
Independent Director
2.59K
+155.42%
Dr. Craig B. Thompson, M.D.
Dr. Craig B. Thompson, M.D.
Independent Director
Independent Director
2.41K
+64.49%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
946.00
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. James C. Foster
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
267.96K
+6.88%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
57.72K
+24.38%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
17.89K
+48.67%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
12.88K
+69.56%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
12.48K
-8.77%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+23.86%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
By BusinessUSD
Name
Revenue
Proportion
DSA
618.03M
59.88%
RMS
213.27M
20.66%
Manufacturing
200.84M
19.46%
By RegionUSD
Name
Revenue
Proportion
United States
549.86M
53.27%
Europe
281.86M
27.31%
Canada
135.59M
13.14%
Asia Pacific (Region)
54.50M
5.28%
Other
10.33M
1.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
DSA
618.03M
59.88%
RMS
213.27M
20.66%
Manufacturing
200.84M
19.46%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.84%
Wellington Management Company, LLP
6.48%
BlackRock Institutional Trust Company, N.A.
5.73%
Allspring Global Investments, LLC
4.43%
State Street Investment Management (US)
3.72%
Other
67.80%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.84%
Wellington Management Company, LLP
6.48%
BlackRock Institutional Trust Company, N.A.
5.73%
Allspring Global Investments, LLC
4.43%
State Street Investment Management (US)
3.72%
Other
67.80%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
44.49%
Investment Advisor
44.48%
Hedge Fund
7.70%
Research Firm
4.24%
Bank and Trust
3.01%
Pension Fund
1.52%
Individual Investor
1.06%
Sovereign Wealth Fund
1.04%
Insurance Company
0.08%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1367
52.25M
129.09%
+28.56K
2025Q3
1413
52.22M
129.54%
+64.86K
2025Q2
1411
52.12M
127.74%
-2.86M
2025Q1
1414
54.69M
123.53%
-5.98M
2024Q4
1410
54.25M
114.75%
+1.17M
2024Q3
1372
53.38M
114.53%
-33.66K
2024Q2
1378
53.46M
111.45%
+347.48K
2024Q1
1371
53.18M
111.09%
-4.05M
2023Q4
1405
52.96M
112.24%
-202.82K
2023Q3
1421
52.99M
111.08%
+631.82K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
5.80M
11.79%
-293.30K
-4.81%
Jun 30, 2025
Wellington Management Company, LLP
3.77M
7.66%
-517.21K
-12.07%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.75M
5.59%
-156.85K
-5.39%
Jun 30, 2025
Allspring Global Investments, LLC
2.29M
4.66%
+516.52K
+29.11%
Jun 30, 2025
State Street Investment Management (US)
1.86M
3.78%
-43.84K
-2.30%
Jun 30, 2025
Ariel Investments, LLC
1.42M
2.88%
+314.57K
+28.58%
Jun 30, 2025
Harris Associates L.P.
1.16M
2.36%
+1.16M
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.23M
2.5%
-31.43K
-2.49%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.01M
2.05%
+148.44K
+17.22%
Jun 30, 2025
Invesco Capital Management LLC
1.09M
2.22%
+110.27K
+11.23%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco S&P 500 Equal Weight Health Care ETF
1.92%
Schwab Ariel Opportunities ETF
1.82%
iShares Health Innovation Active ETF
1.74%
First Trust NASDAQ Pharmaceuticals ETF
1.71%
ROBO Global Healthcare Technology & Innovation ETF
1.69%
VanEck Biotech ETF
1.44%
Franklin Genomic Advancements ETF
1.42%
WisdomTree US Value Fund
1.15%
Invesco S&P 500 High Beta ETF
1.14%
Pacer Lunt Large Cap Alternator ETF
0.97%
View more
Invesco S&P 500 Equal Weight Health Care ETF
Proportion1.92%
Schwab Ariel Opportunities ETF
Proportion1.82%
iShares Health Innovation Active ETF
Proportion1.74%
First Trust NASDAQ Pharmaceuticals ETF
Proportion1.71%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.69%
VanEck Biotech ETF
Proportion1.44%
Franklin Genomic Advancements ETF
Proportion1.42%
WisdomTree US Value Fund
Proportion1.15%
Invesco S&P 500 High Beta ETF
Proportion1.14%
Pacer Lunt Large Cap Alternator ETF
Proportion0.97%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Charles River Laboratories International Inc?
The top five shareholders of Charles River Laboratories International Inc are:
The Vanguard Group, Inc. holds 5.80M shares, accounting for 11.79% of the total shares.
Wellington Management Company, LLP holds 3.77M shares, accounting for 7.66% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.75M shares, accounting for 5.59% of the total shares.
Allspring Global Investments, LLC holds 2.29M shares, accounting for 4.66% of the total shares.
State Street Investment Management (US) holds 1.86M shares, accounting for 3.78% of the total shares.
The Vanguard Group, Inc. holds 5.80M shares, accounting for 11.79% of the total shares.
Wellington Management Company, LLP holds 3.77M shares, accounting for 7.66% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.75M shares, accounting for 5.59% of the total shares.
Allspring Global Investments, LLC holds 2.29M shares, accounting for 4.66% of the total shares.
State Street Investment Management (US) holds 1.86M shares, accounting for 3.78% of the total shares.
What are the top three shareholder types of Charles River Laboratories International Inc?
The top three shareholder types of Charles River Laboratories International Inc are:
The Vanguard Group, Inc.
Wellington Management Company, LLP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Wellington Management Company, LLP
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Charles River Laboratories International Inc (CRL)?
As of 2025Q4, 1367 institutions hold shares of Charles River Laboratories International Inc, with a combined market value of approximately 52.25M, accounting for 129.09% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.45%.
What is the biggest source of revenue for Charles River Laboratories International Inc?
In FY2025Q2, the DSA business generated the highest revenue for Charles River Laboratories International Inc, amounting to 618.03M and accounting for 59.88% of total revenue.
